Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company